Today: 21 May 2026
Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
10 January 2026
1 min read

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

London, Jan 10, 2026, 09:40 GMT — Market closed

  • Lloyds ended Friday up 0.25% at 100.30 pence, just above the £1 mark
  • UK inflation data is due on Jan 21, with the Bank of England’s next rate decision on Feb 5
  • Lloyds is set to publish preliminary 2025 results on Jan 29

Lloyds Banking Group (LLOY.L) shares ended Friday up 0.25% at 100.30 pence, keeping the stock just above the £1 mark after a choppy session. The lender is up about 86% over the past year and traded between 99.46 and 101.95 pence on the day, according to Hargreaves Lansdown data. About 54.5 million shares changed hands.

The £1 handle has become a line in the sand for some traders after the run-up, and the stock has started to move in shorter bursts. Lloyds rose 1.16% on Thursday and sat about 1.67% below a 52-week high of £1.02, MarketWatch data showed.

Rate expectations sit at the centre of the debate for UK-focused lenders. A Bank of England survey showed firms trimmed wage and price growth expectations only slightly, leaving policymakers wary. “The Monetary Policy Committee will have to be cautious, so we are comfortable assuming only one more rate cut this year,” said Rob Wood, chief UK economist at Pantheon Macroeconomics. Reuters

UK consumer price inflation data for December is due on Jan 21, and it can reset bets on how quickly the BoE eases policy.

The BoE’s next policy decision is scheduled for Feb 5, its first rate call of 2026. Investors will pick through the minutes for any hint on how far and how fast rates could move.

For Lloyds, the closer marker is its preliminary results for 2025 on Jan 29. Traders will focus on net interest margin — the gap between what a bank earns on loans and pays on deposits — and whether the lender keeps room for capital returns.

But a quicker slide in rates would squeeze lending margins, while a softer UK economy could lift bad-debt charges. A separate overhang is a potential industry-wide redress bill linked to mis-sold car loans, which sources have said could run beyond regulators’ earlier estimates.

Next up are the Jan 21 inflation print and Lloyds’ Jan 29 results, with the BoE decision on Feb 5 close behind. Monday’s session will show whether the shares can hold above 100 pence without fresh company news.

Stock Market Today

  • EnerSys Q1 CY2026 Sales Beat Estimates with Optimistic Guidance
    May 20, 2026, 6:18 PM EDT. Battery maker EnerSys (NYSE:ENS) reported Q1 CY2026 sales of $988 million, up 1.4% year on year, beating analyst estimates by 1.5%. Adjusted earnings per share (EPS) stood at $3.19, a 6.6% beat over consensus. Guidance for Q2 revenue is $935 million, 2.2% above estimates, with adjusted EPS guidance also exceeding forecasts. Despite a 6% decline in sales volumes, revenue growth was supported by price increases. Free cash flow turned negative at -$12.66 million, down from $105 million last year. EnerSys continues to push its lithium data center and battery energy storage system solutions, signaling long-term innovation. The company's subdued 4.7% annualized revenue growth over five years contrasts with sector expectations, raising caution among investors.

Latest articles

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

21 May 2026
AEVEX Corp. shares surged over 10% after hours Wednesday following a first-quarter profit of $21 million and new U.S. Air Force contracts worth $15.6 million. Revenue jumped to $216.7 million, beating estimates. The company, which went public in April, raised its full-year revenue outlook to $600–$620 million. The stock had closed regular trading at $26.27, down 0.23%.
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

21 May 2026
Jupiter Neurosciences shares fell 37% to $0.205 Wednesday after announcing a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 and a $2 million stock offering. Trading volume topped 230 million shares. The licensing agreement is non-binding, with a potential value over $100 million, and gives Jupiter 90 days to finalize terms. Jupiter reported a $2.06 million Q1 net loss and $2.36 million in cash.
Urban Outfitters Stock Swings After Record Q1—What Nuuly and Tariffs Are Telling Investors

Urban Outfitters Stock Swings After Record Q1—What Nuuly and Tariffs Are Telling Investors

21 May 2026
Urban Outfitters posted record first-quarter net income of $115.7 million and sales of $1.48 billion, beating analyst estimates. Shares closed up 4.05% at $71.67 before slipping to $70.55 in after-hours trading. Comparable retail sales rose 5.6%, with strong gains at FP Group, Urban Outfitters, and Nuuly. Gross profit rate edged down to 36.6% as tariffs pressured costs.
Bank of America stock dips after-hours after $3 billion debt call, with earnings next week
Previous Story

Bank of America stock dips after-hours after $3 billion debt call, with earnings next week

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy
Next Story

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

Go toTop